Skip to main
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio is an attractive investment opportunity due to the potential success of their lead candidate, buntanetap, in treating Alzheimer's disease, Parkinson's disease, and Lewy body dementia. Positive results from ongoing clinical trials, such as the reduction of sAPP in early Alzheimer's patients and the ongoing enrollment in the Phase 3 open-label extension study for Parkinson's disease, provide strong support for the company's promising mechanism of action and potential market opportunity. This, combined with the recent raise securing their funding needs and a potential 1Q27 trial readout, make ANVS significantly undervalued with the potential for high returns in the future.

Bears say

Annovis Bio is facing challenges in gaining approval for their flagship drug buntanetap, as the likelihood of approval is estimated at 25%. The company's expected peak sales in 2037 are moderately low at $2.5 billion, indicating that their product may have limited market potential. In addition, their reliance on future raises and regulatory milestones for financial success may pose a risk to investors.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.